Editorial
Role for miR-29b suppression in multiple myeloma
Abstract
Multiple myeloma (MM) is a common hematologic malignancy of the elderly, accounting for 2% of cancer deaths, in which malignant plasma cells proliferate in the bone marrow resulting in bone disease and immunosuppression (1,2).
